Zal Bilimoria’s Post

Can AI transform cancer diagnostics and treatment on a global scale? In Episode Two of Startup Insider, a new series from Startup Daily and Dell Technologies, the founders of NanoCube Health – Lisa Milani and Dr Shawn Goussous – test the limits of what’s possible and attract interest from abroad. Watch the four-part series here: https://lnkd.in/ga2MJSAc

📰 Exciting news for biotech founders! J.P. Morgan Private Capital just closed their first biotechnology-focused fund, raising over $500 million from a mix of backers like family offices, corporate partners, and institutional investors. Led by Stephen Squinto and Gaurav Gupta, the fund plans to make 20 to 25 investments in early-stage biotech companies spanning cardiometabolic disease, immunology, oncology, and genetic medicine. Dive into their strategy and vision for shaping the future of patient care in biotech: bit.ly/3KLxU8I

When one door closes for you; how you pivot into a newly opening door is key. This blog offers an inside view in real time. Tap in and enjoy this amazing ride: Embracing Change: From Corporate to Creative In life, the unexpected can reshape our paths. Join me as I share my journey from a promising corporate career, through the challenges of battling breast cancer, to a newfound creative venture. It's a story of resilience, reinvention, and the pursuit of passion. Read my latest blog post and find inspiration to navigate your unique journey. https://lnkd.in/e6xcWwdX

Cure51 (www.cure51.com) is on a mission to unlock the mysteries behind the survival of the few who beat the most lethal cancers. Instead of learning from the data from the 97% of patients who die from the most lethal cancers, Cure51 focuses on the outliers, the miraculous 3% of patients who survive, to understand what keeps them alive. They are building the most comprehensive molecular database using the latest multiomics techniques. A comprehensive analysis of these #Outliers may help to contribute to the development of potential new treatments. Their goal is ambitious yet clear: To turn everyone into an outlier. We're thrilled to join forces with Sofinnova Partners, Hitachi Ventures, Xavier Niel, and Olivier Pomel in supporting Cure51's groundbreaking approach. Nicolas Wolikow Simon Turner Simon Istolainen LifeX Ventures

With the work Joan Chen, Ph.D does at Boundless Bio, every query is unique. As our Sr. Director, Bioinformatics, Joan is inspired by the creative challenges she encounters and appreciates the chance to be involved in impactful work for patients.   Joan is one of the many dedicated and unique BoundTowners on our team pushing to make steps in a new frontier in oncology. See more about her in her “Boundless Bio!”

It's important to recognize the real people and dedication that goes on behind the scenes. Today at #DELFI, we want to take a moment to celebrate these individuals' promotions. Their contributions have not only moved us forward but have set new benchmarks for excellence. Your hard work, innovative thinking, and commitment to making a difference in early cancer detection inspire us all. #InnovativeResearch #Biotechnology #CancerResearch #DELFI

🚀 𝗦𝗧𝗔𝗥𝗧𝗨𝗣 𝗖𝗢𝗥𝗡𝗘𝗥 🚀 🚀 Introducing BlueRock Therapeutics! 🌟 This groundbreaking startup is redefining the future of regenerative medicine. 💡 With cutting-edge technology, they develop innovative treatments to heal and restore the body. 🌱 Join their mission to unlock the full potential of stem cells and transform lives. 🌈 What are your thoughts on this revolutionary approach? Share your ideas below! 👇

Knowing how to pitch your cancer technology to potential investors and strategic partners is critical to obtaining follow-on funding to reach commercialization. Watch this clip to learn the basics of pitching. 

Did you sink your battleship ⛴️? (do you remember playing that game?!) The battleship here is your strategy to achieve a goal And if your battleship has sunk (you didn’t complete said goal), it means you need to rethink your strategy, and it doesn’t involve a recon mission to the bottom of the sea to salvage your old one 😅 Learning about the sunk cost fallacy was super helpful to me when dealing with my own sunk battleship A sunk cost is something that you paid for in the past (either in your time 🕑 or with your money 💵) that is not relevant to future decisions My PGY2 research manuscript was a sunk cost. I invested a lot of time trying to resurrect that thing from the bottom of the ocean. Why? Because I had invested so much time into the research, the writing, the (endless) editing, and was so close to seeing it published it was blinding me. I was throwing “good money after bad” Just because you invested in something in the past, doesn’t mean you should double down on it. That investment is gone and it’s not coming back. Make a new decision now to direct future strategy No one likes feeling like they wasted time or money, but it’s even worse to not learn the lesson and waste even more the second go around --- 📌 Whenever you’re ready to prioritize learning oncology, the Enjoy Learning Oncology (ELO) program can help you! Check out the **LEARN ONCOLOGY** link in my profile. I’m the Kelley in KelleyCPharmD 👋 and I help pharmacists learn the complex world of oncology #LearnOncology #Pharmacists #OncologyPharmacists #Oncology

BrightEdge - American Cancer Society : Where venture capital meets impact investing to accelerate the fight against cancer. Together, BrightEdge is shaping the future of cancer care and Alice Lin Pomponio's mission is changing lives. Catch it all on Boston Speaks Up with Zach Servideo! 💙 https://lnkd.in/egTAeu9Q #BrightEdge #ImpactInvesting #BostonBusiness #BostonPodcasts